IL6 and neoplasm: Although spatially resolved platforms like IMC have shown promise in identifying immunotherapy responders across cancers, including melanoma and breast cancer [20,21], our study employed the Multiplex Luminex Assay to quantify key cytokines, such as IL-6 and IL-23, which may represent critical nodes in immune regulation within the tumor microenvironment.